InvestSMART

Resonance Health Limited (ASX:RHT)

ALERT: Price-sensitive ASX Announcement for RHT
Current share price for RHT : $0.048 0.005 (11.63%)+
Announcement
Release
29 Apr 2026 8:51AM
Price at Release
$0.043
Full Release
download
Summary
Resonance Health Limited, an Australian healthcare technology company, has released its quarterly activities and cash flow report for the period ending 31 March 2026. The company reported cash receipts of $4.4M and a net operating cash inflow of $2.0M, with a net cash position of $1.8M after accounting for debt. Major highlights include nearing completion of a $13.8M clinical trial, strong international demand for its SaMD products, and expansion of its TrialsWest clinic network. Additionally, the proof-of-concept trial for its non-invasive MRI liver fibrosis product has completed enrolment, and two new non-executive directors have been appointed to strengthen the board.
Key Points
  • Cash receipts of $4.4M with net operating cash inflow of $2.0M.
  • The Group received a net R&D claim refund of $0.7M.
  • Cash at bank of $4.4M at quarter-end with a net cash position of $1.8M after accounting for $2.6M in bank debt.
  • Major pharma $13.8M clinical trial recruitment target expected to complete in April 2026.
  • Continued strong Software-as-a-Medical-Device (SaMD) bid activity with forward orders and pipeline exceeding $10M.
  • TrialsWest Osborne Park clinic exceeding expectations, with the Mandurah clinic also performing well.
  • Completion of patient enrolment in the Non-Invasive MRI Liver Fibrosis proof-of-concept trial.
  • Appointment of two Non-Executive Directors to strengthen Board capability.
  • Focus on growth in three core business areas: Clinical Trial Management, SaMD, and Clinical Trial Site Services.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.